699 - Prevalence and incidence of atopic dermatitis in patients with alopecia areata in the United States: a population-based study
Arash Mostaghimi(Brigham and Women's Hospital), Christopher G. Bunick(Yale University), Dawid Lipiszko(AbbVie (United States)), Claire Bristow(AbbVie (United States)), Ayman Grada(University Hospitals of Cleveland), Chao Li(Eli Lilly (United States)), April W. Armstrong(University of Southern California), Naiem T. Issa(University of Miami), Ahmed M. Soliman(AbbVie (United States)), Jonathan I. Silverberg(George Washington University)
Cited by 1
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Genomic landscape of cutaneous T cell lymphoma
|Nature Genetics|2015|418
Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trials
|British Journal of Dermatology|2020|389
Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder
|Journal of Investigative Dermatology|2016|377
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
|Journal of Allergy and Clinical Immunology|2019|363